Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Clinical trial NCT05712200 · RECRUITING
Trial details
- NCT number
- NCT05712200
- Sponsor
- Anthos Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-27
- Primary completion
- 2027-12-30
- Enrollment
- 2500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.